Investigational drug · Phase 2
endoxifen
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Precocious Puberty, Gonadotropin-dependent, Breast Neoplasms, Invasive Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
19
Any phase or sponsor naming "endoxifen"
First trial start
2023
Feb 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "endoxifen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Precocious Puberty, Gonadotropin-dependent
- Breast Neoplasms
- Invasive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- HER2-negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "endoxifen" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancERPivotal-lookingRecruiting
Karolinska InstitutetAcademic, hospital or other
NCT07502820 · 1,100 participants (planned) · Start Apr 14, 2026 · Primary completion Aug 2036
Drug: Individual dose of tamoxifen; Standard adjuvant therapy of tamoxifen · For: Breast Cancer; Adjuvant Drug Therapy
Sites: Borås, Sweden; Skövde, Sweden; Stockholm, Sweden · 4 sites in all
- Efficacy and Safety of Endoxifen in Bipolar I Disorder PatientsPivotal-lookingStatus unknown
Jina Pharmaceuticals Inc.Industry
NCT06608641 · 490 participants (planned) · Start Mar 19, 2024 · Primary completion Jun 2025
Drug: Endoxifen enteric-coated tablet (8 mg); Placebo Tablets · For: Bipolar 1 Disorder
Sites: Cerritos, California; Los Angeles, California; Orange, California · 12 sites in all
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT06075953 · 400 participants (planned) · Start Feb 17, 2024 · Primary completion Nov 2028
Drug: Tamoxifen; Exemestane and 5 more · For: Ductal Carcinoma in Situ
Sites: Berkeley, California; Duarte, California; Irvine, California · 31 sites in all
- Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer PatientsPivotal-lookingCompleted
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)Academic, hospital or other
NCT03931928 · 356 participants · Start Sep 10, 2019 · Primary completion May 3, 2021
Drug: (Z)-Endoxifen supplementation according to genotype; (Z)-Endoxifen supplementation according to plasma levels · For: Breast Cancer; DCIS
Sites: Salzgitter, Germany; Suhl, Germany; Winnenden, Germany · 40 sites in all
- Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast DensityPivotal-lookingCompleted
Atossa Therapeutics, Inc.Industry
NCT05068388 · 240 participants · Start Dec 21, 2021 · Primary completion Jun 14, 2024
Drug: Z-Endoxifen; Placebo · For: Breast Density
Sites: Stockholm, Sweden
Nalagenetics Pte LtdIndustry
NCT04312347 · 151 participants · Start Sep 6, 2019 · Primary completion May 1, 2021
Drug: Tamoxifen dose adjustment · For: ER+ Breast Cancer
Sites: Jakarta, Indonesia
Nalagenetics Pte LtdIndustry
NCT05501158 · 150 participants · Start Jan 1, 2021 · Primary completion Apr 30, 2024
Drug: Tamoxifen · For: Breast Cancer
Sites: Jakarta, Indonesia
- Tamoxifen Citrate in Patients With Breast CancerPivotal-lookingStatus unknown
Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
NCT00963209 · 140 participants (planned) · Start Jun 2009 · Primary completion Sep 2013
Drug: tamoxifen citrate · For: Breast Cancer
Sites: Geneva, Switzerland; Lausanne, Switzerland
- Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder PatientsPivotal-lookingCompleted
Jina Pharmaceuticals Inc.Industry
NCT04315792 · 124 participants · Start Aug 3, 2020 · Primary completion Jan 25, 2021
Drug: Endoxifen; Placebo oral tablet · For: Bipolar I Disorder
Sites: Miami, Florida
Newest research
PubMed records naming it or its code names, newest first.
- A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 Allelic Percentage Activity from the International CEPAM Database.
Klima F, Helland T, Michelet R, et al. · Clin Pharmacol Ther 2026
- Endoxifen for urge-driven behavioural dyscontrol: Clinical observations in compulsive buying and gambling disorder.
Sahoo S, Rudwinga A, Chakravarty R · Asian J Psychiatr 2026
- Model-based exploration of tamoxifen therapy: addressing exposure and the influence of albumin on proposed endoxifen threshold concentration levels.
Turner N, Mattison D, Jin K, et al. · Anticancer Drugs 2026
- Measurement of Tamoxifen and Endoxifen Concentrations via Liquid Chromatography-Tandem Mass Spectrometry to Assess Adherence and Optimal Concentrations in South Africans with Breast Cancer Participating in a Pilot Trial: A Short Communication.
Govender JT, Edge JM, Thebe TT, et al. · Ther Drug Monit 2026
- Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.
Hall P, Hammarström M, Bergqvist J, et al. · J Natl Cancer Inst 2026
- Rapidly Enlarging Multiloculated Ovarian Cyst With Dramatic Interval Regression Following Endoxifen Discontinuation in an Adolescent Psychiatric Patient: A Probable Adverse Drug Reaction.
Garg S, Anand A, Gupta V · J Clin Psychopharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.